Marc Goodman
Stock Analyst at Leerink Partners
(4.61)
# 738
Out of 5,182 analysts
100
Total ratings
59.76%
Success rate
23.7%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Outperform | $160 → $170 | $128.04 | +32.77% | 5 | Apr 22, 2026 | |
| MANE Veradermics | Maintains: Outperform | $75 → $90 | $100.10 | -10.09% | 2 | Apr 22, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $215 → $225 | $201.22 | +11.82% | 6 | Apr 22, 2026 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $40 → $35 | $19.94 | +75.53% | 2 | Apr 22, 2026 | |
| DFTX Definium Therapeutics | Maintains: Outperform | $23 → $30 | $20.98 | +42.99% | 1 | Apr 22, 2026 | |
| SGP SpyGlass Pharma | Initiates: Outperform | $42 | $23.52 | +78.57% | 1 | Mar 3, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $187.40 | +9.39% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $2.22 | +260.36% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $30.64 | -2.09% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $2.69 | +85.87% | 1 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $31.81 | +6.88% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $50 | $9.59 | +421.38% | 7 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $10 | $16.88 | -40.76% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $10 → $1 | $7.03 | -85.78% | 3 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $9.76 | +227.87% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $163.06 | -84.67% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $5.22 | +283.14% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $180.67 | +71.58% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $54.26 | -15.22% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $22.30 | -5.83% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.84 | +252.11% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $33.73 | -19.95% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $1.58 | +849.37% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $539.66 | -49.97% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $197.38 | -51.36% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.78 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $110.23 | -39.22% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $11.49 | +752.92% | 7 | Oct 5, 2017 |
Neurocrine Biosciences
Apr 22, 2026
Maintains: Outperform
Price Target: $160 → $170
Current: $128.04
Upside: +32.77%
Veradermics
Apr 22, 2026
Maintains: Outperform
Price Target: $75 → $90
Current: $100.10
Upside: -10.09%
Jazz Pharmaceuticals
Apr 22, 2026
Maintains: Outperform
Price Target: $215 → $225
Current: $201.22
Upside: +11.82%
Denali Therapeutics
Apr 22, 2026
Maintains: Outperform
Price Target: $40 → $35
Current: $19.94
Upside: +75.53%
Definium Therapeutics
Apr 22, 2026
Maintains: Outperform
Price Target: $23 → $30
Current: $20.98
Upside: +42.99%
SpyGlass Pharma
Mar 3, 2026
Initiates: Outperform
Price Target: $42
Current: $23.52
Upside: +78.57%
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $187.40
Upside: +9.39%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $2.22
Upside: +260.36%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $30.64
Upside: -2.09%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $2.69
Upside: +85.87%
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $31.81
Upside: +6.88%
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $9.59
Upside: +421.38%
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $16.88
Upside: -40.76%
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $7.03
Upside: -85.78%
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $9.76
Upside: +227.87%
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $163.06
Upside: -84.67%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $5.22
Upside: +283.14%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $180.67
Upside: +71.58%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $54.26
Upside: -15.22%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $22.30
Upside: -5.83%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.84
Upside: +252.11%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $33.73
Upside: -19.95%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $1.58
Upside: +849.37%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $539.66
Upside: -49.97%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $197.38
Upside: -51.36%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $57.78
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $110.23
Upside: -39.22%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $11.49
Upside: +752.92%